| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Preuss Laboratory for Brain Tumor Research [D. M. A., D. D. B.], Laboratory of Molecular Immunopathology [D. M. A., L. P. H.], and Department of Radiation Oncology [F. M. K.], Duke University Medical Center, Durham, North Carolina 27710
It has been hypothesized that transforming growth factor ß (TGF-ß) may prevent immune-mediated glioma cell elimination; however, previous work has also indicated that increased TGF-ß may lead to reduced proliferation, induction of apoptosis, and enhancement of Fas-induced apoptosis. We have investigated the role of TGF-ß in the progression of malignant glioma using an immunocompetent murine model. SMA 560 malignant glioma cells were stably transfected with constructs that resulted in over- or underproduction of active TGF-ß1. Using these cell lines, we have shown that (a) TGF-ß1 inhibits induction of antitumor cytotoxicity when the tumor cells are given s.c. but not when they are given intracranially; (b) Fas/APO-1 is expressed on SMA 560 cells in vitro and in vivo, SMA 560 cells are susceptible to TGF-ß1- and Fas-induced apoptosis in vitro, and TGF-ß1 and Fas act synergistically to induce glioma cell death; (c) increased levels of endogenous TGF-ß1 production by SMA 560 cells lead to increased sensitivity to Fas-mediated apoptosis; (d) overproduction of endogenous TGF-ß1 reduces the rate of s.c. SMA 560 tumor growth and also reduces the tumorigenicity of tumors located in the central nervous system, with opposite effects observed with underproduction of TGF-ß1 using antisense cell lines; and (e) the observed changes in growth parameters in vivo were associated with increased rates of apoptosis in TGF-ß1-overproducing cells. Taken together, these results indicate that, despite decreased induction of CTL responses, the dominant net effect of TGF-ß1 on the growth of the SMA 560 murine high-grade glioma in vivo is growth inhibition. This contrasts with results seen with non-central nervous system malignant tumors in immunocompetent animals, in which TGF-ß1 production provides a major growth advantage.
1 This work was supported by NIH Grants CA61227 (to L. P. H.) and CA11898 and NS 20023 (both to D. D. B.), the Pediatric Brain Tumor Foundation (to D. D. B.), and a Children's Miracle Network grant (to D. M. A.). D. M. A. is the recipient of an Australian National Health & Medical Research Council Neil Hamilton Fairley Fellowship.
2 To whom requests for reprints should be addressed. Phone: (919) 684-5018; Fax: (919) 684-5231.
Received 5/ 5/97. Accepted 11/12/97.
This article has been cited by other articles:
![]() |
M. Uhl, S. Aulwurm, J. Wischhusen, M. Weiler, J. Y. Ma, R. Almirez, R. Mangadu, Y.-W. Liu, M. Platten, U. Herrlinger, et al. SD-208, a Novel Transforming Growth Factor {beta} Receptor I Kinase Inhibitor, Inhibits Growth and Invasiveness and Enhances Immunogenicity of Murine and Human Glioma Cells In vitro and In vivo Cancer Res., November 1, 2004; 64(21): 7954 - 7961. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Itano, T. Sawai, F. Atsumi, O. Miyaishi, S. Taniguchi, R. Kannagi, M. Hamaguchi, and K. Kimata Selective Expression and Functional Characteristics of Three Mammalian Hyaluronan Synthases in Oncogenic Malignant Transformation J. Biol. Chem., April 30, 2004; 279(18): 18679 - 18687. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. D. Riffkin, A. Z. Gray, C. J. Hawkins, C.W. Chow, and D. M. Ashley Ex vivo pediatric brain tumors express Fas (CD95) and FasL (CD95L) and are resistant to apoptosis induction Neuro-oncol, October 1, 2001; 3(4): 229 - 240. [Abstract] [PDF] |
||||
![]() |
N. Dunker, N. Schuster, and K. Krieglstein TGF-{beta} modulates programmed cell death in the retina of the developing chick embryo Development, June 1, 2001; 128(11): 1933 - 1942. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. W. Tobin, M. K. Brown, K. Douville, D. C. Payne, A. Eastman, and B. A. Arrick Inhibition of Transforming Growth Factor {beta} Signaling in MCF-7 Cells Results in Resistance to Tumor Necrosis Factor {{alpha}}: A Role for Bcl-2 Cell Growth Differ., February 1, 2001; 12(2): 109 - 117. [Abstract] [Full Text] |
||||
![]() |
G. J. Inman and M. J. Allday Apoptosis Induced by TGF-{beta}1 in Burkitt's Lymphoma Cells Is Caspase 8 Dependent But Is Death Receptor Independent J. Immunol., September 1, 2000; 165(5): 2500 - 2510. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.A. Garcia-Velasco, A. Arici, T. Zreik, F. Naftolin, and G. Mor Macrophage derived growth factors m odulate Fas ligand expression in cultured endometrial stromal cells: a role in endometriosis Mol. Hum. Reprod., July 1, 1999; 5(7): 642 - 650. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Yu, K. Israel, Q. Y. Liao, C. M. Aldaz, B. G. Sanders, and K. Kline Vitamin E Succinate (VES) Induces Fas Sensitivity in Human Breast Cancer Cells: Role for Mr 43,000 Fas in VES-triggered Apoptosis Cancer Res., February 1, 1999; 59(4): 953 - 961. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Choudhury, R. K. Singh, N. Moniaux, T. H. El-Metwally, J.-P. Aubert, and S. K. Batra Retinoic Acid-dependent Transforming Growth Factor-beta 2-mediated Induction of MUC4 Mucin Expression in Human Pancreatic Tumor Cells Follows Retinoic Acid Receptor-alpha Signaling Pathway J. Biol. Chem., October 20, 2000; 275(43): 33929 - 33936. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |